Company Description
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States.
Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19.
The company is headquartered in Englewood, Colorado.
| Country | United States |
| IPO Date | Mar 31, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Michael A. Martino |
Contact Details
Address: 373 Inverness Parkway Englewood, Colorado United States | |
| Website | https://www.ampiopharma.com |
Stock Details
| Ticker Symbol | AMPE |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001411906 |
| CUSIP Number | 03209T109 |
| ISIN Number | US03209T3077 |
| Employer ID | 26-0179592 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael A. Martino | Chief Executive Officer, Chief Financial Officer, General Secretary & Director |
| April Ramirez | Clinical Trial Manager |
| Dr. David Bar-Or M.D. | Founder & Chairman of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 15-12G | Filing |
| Apr 04, 2024 | 25 | Filing |
| Mar 27, 2024 | 10-K | Annual Report |
| Mar 25, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 28, 2024 | S-8 POS | Filing |
| Feb 28, 2024 | S-8 POS | Filing |
| Feb 28, 2024 | POS AM | Filing |
| Feb 28, 2024 | RW | Filing |
| Feb 15, 2024 | 8-K | Current Report |